Table 1

Baseline cardiovascular measures of controls, low risk and newly identified high QRISK3 patients with SLE

VariableControls (n=29)Newly identified high QRISK3 patients* (n=21)P valuesLow-risk patients with SLE (n=80)Newly identified high QRISK3 patients*(n=21)P values
Age (years),mean±SD36.66±12.9542.16±12.360.13038.02±10.6842.16±12.360.155
Ethnicity: Caucasian23(79%)13(62%)0.21358(73%)13(62%)0.292
BMI (kg/m2)22.6(21.3,25.3)31.8(24.3,37.0) 0.003 25.3(22.2,28.4)31.8(24.3,37.0) 0.026
BP systolic (mm Hg)118.0(111.0,130.0)141.0(127.0,159.0) 0.001 122.0(110.8,128.3)141.0(127.0,159.0) < 0.001
HDL cholesterol (mmol/L)1.7(1.5,2.0)1.5(1.3,1.8) 0.037 1.7(1.2,2.0)1.5(1.3,1.8)0.222
Non-HDL cholesterol (mmol/L)2.6(2.3,3.2)3.2(2.5,3.6)0.1152.7(2.2,3.2)3.2(2.5,3.6)0.053
Type 2 diabetes0(0%)3(14%)1.0000(0%)3(14%) 0.008
Rheumatoid arthritis0(0%)0(0%)1.0005(6%)0(0%)0.312
Chronic kidney disease(stages3–5)0(0%)5(24%) 0.010 3(4%)5(24%) 0.021
Severe mental illness2(7%)2(9%)1.0003(4%)2(9%)0.277
Current smoker4(14%)6(29%)0.28615(19%)6(29%)0.368
Antihypertensive3(10.34%)15(71%) < 0.001 13(16%)14(67%) < 0.001
Current oral corticosteroids0(0%)21(100%) < 0.001 46(58%)21(100%) < 0.001
  • Variables included in QRISK3 algorithm are shown; severe mental illness inclusive of depression, schizophrenia and bipolar disorder. Unless otherwise stated, values are shown as number (percentage) or median (lower, upper quartile). Data were analysed by Mann-Whitney U and Fisher’s exact tests as appropriate.

  • Bold type denotes p<0.05.

  • *Newly identified high QRISK3 patientsrefers to patients with SLEnewly identified as possessing high cardiovascular risk (≥10%) when using QRISK3 vsQRISK2. Patients with SLEidentified as high risk by both algorithms were not included in the analysis (n=8).

  • BMI, Body Mass Index;BP, blood pressure;HDL, high-density lipoprotein.